|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The haplotype background of TP53 gene is relative stable and despite low haplotype-regressor cccgaRDa frequency it shows to be a possible predictive parameter for CRC development.
|
28373458 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Three p53 DNA polymorphisms (BstU I and Msp I restriction fragment length polymorphisms (RFLPs) in exon 4 and intron 6 respectively, and a 16 bp duplication in intron 3) and their haplotype combinations were studied in patients with colorectal cancer and compared with patients with ulcerative colitis and healthy controls.
|
7614678 |
1995 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, the routine sequencing of the entire TP53 gene in all breast and colorectal cancer cases in hospital laboratories is prohibitively costly, complex, and time consuming.
|
10718211 |
2000 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutation of p53 was also found more frequently in aneuploid populations of early multiploid colorectal carcinomas than in early diploid colorectal carcinomas (66.7% vs 0%, p = 0.021).
|
12754737 |
2003 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs.
|
29860032 |
2019 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In longstanding IBD, abnormal DNA ploidy and p53 immunopositivity are important risk factors of developing CRC.
|
21327897 |
2011 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We tested the association of MGMT methylation with G > A mutations in KRAS and TP53 in 261 CRCs.
|
25638164 |
2015 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
CDK1 interacts with iASPP to regulate colorectal cancer cell proliferation through p53 pathway.
|
29069733 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA and BRAF were exhibited by 5 and 4 of the patients with CRC.TP53 mutants exhibited higher SUV(max).
|
26018692 |
2015 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In contrast, p53 family member p73 is rarely mutated in colorectal cancer and p73 activation elicits p53-like tumor suppression.
|
26759239 |
2016 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
|
2649981 |
1989 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
|
30107178 |
2018 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To investigate whether tumor manipulation during operation enhances cancer cell dissemination into the portal vein with use of MASA and to assess the effect of the no-touch isolation technique in the treatment of colorectal cancers, 27 colorectal cancers (17 were operated on conventionally and 10 were operated on according to the no-touch isolation technique) were screened for mutations in K-ras or p53.
|
10216526 |
1999 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Taken together, this meta-analysis suggested that the biologically usefulness of TP53 codon 72 polymorphism as a selection marker in colorectal cancer susceptibility may be very limited.
|
21140221 |
2011 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Two isogenetic human colorectal cancer cell lines with wild-type TP53 status were used.
|
12859231 |
2003 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression of p53 protein in invasive colorectal carcinomas of different histologic types.
|
1451054 |
1992 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Together our studies suggest that PARP inhibitors may have potential for treating colorectal cancer with ATM dysfunction and/or colorectal cancer with mutation of p53 when combined with an ATM kinase inhibitor.
|
28182994 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
|
26294215 |
2015 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We evaluated p53 gene mutations in colorectal carcinomas.
|
7677190 |
1995 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggested that HNK may be a promising anticancer drug for CRC; activation of p53 plays an important role in the anticancer activity of HNK, which may be initialized partly by the HNK-induced upregulation of BMP7.
|
28731124 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Poorer survival of HIF-2 alpha and CA9 stromal-positive CRCs was associated with wild-type TP53 (P=0.001 and P=0.0391), but not with BNIP3 methylation.
|
18728663 |
2008 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that immunohistochemical analysis of p53 expression provides valuable information for the understanding of colorectal cancer biology and clinical behavior.
|
8623770 |
1996 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of CNPY2 in the HCT116 CRC cell line reversibly increased p53 activity.
|
26835537 |
2016 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analysis of TP53 mutations from a large cohort of CRC patients has identified tumor site, type of mutation, and adjuvant treatment as important factors in determining the prognostic significance of this genetic alteration.
|
16172461 |
2005 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to examine the relationship between apoptosis and cell proliferation in various macroscopic types of intramucosal colorectal carcinoma in relation to the expression of p53 and bcl-2.
|
9823803 |
1998 |